We shape science into meaningful solutions that help people live longer, better lives.
Why it matters
When we offer new sustainable solutions to address unmet patient needs, we help improve health outcomes for more people and communities globally.
Our priorities
Innovating to improve patient lives
By generating clinical evidence, investing in R&D, pursuing partnerships and leveraging artificial intelligence, we strive to meet evolving patient needs with new health care solutions.
Ensuring quality, health and safety
Our highest priority is to ensure our products are safe and reliable. Quality is embedded across all our development processes.
Advancing health access and equity
We leverage health economics, clinical outcomes and real-world data to grow the reach of our products and help lessen inequities in health care.
2023 highlights
37M+
patients served
$1.4B
annual R&D spend1
63
active clinical trials
Zero
findings resulting in action following more than 415 external audit days
1. Represents GAAP R&D expense per Annual Report on Form 10-K.
Stories of impact
INNOVATION
Bridging the distance at the touch of a button
Through our RhythmCare™ Support Hub, solutions and therapy experts provide real-time and on-demand support to physicians regardless of their location or time zone. — Learn more about our solutions
ACCESS
On-demand digital platforms empower and support health care providers
In 2023, over 59,000 health care professionals in more than 145 countries accessed our EDUCARE platform. This on-demand platform and our ExpertLink remote connectivity solutions offer learning tools and videos, remote preceptorships, proctorships, case support and equipment assistance so providers can stay connected to our clinical and technical experts as they deliver care to patients. — Learn more about ExpertLink
INNOVATION
Eugénia’s recovery from endometriosis thanks to innovative cryoablation therapy
Cryoablation involves using a hollow probe or catheter, guided by medical imaging, to deliver extremely cold liquid to freeze and destroy targeted tissue, while the surrounding tissue is left intact. Initially used mainly for cancer, cryoablation therapy is increasingly being used to target endometrial lesions. — Read Eugénia's story
ACCESS
Boston Scientific Foundation Europe celebrates its fifth anniversary
2023 marks the fifth anniversary of the Boston Scientific Foundation Europe (BSFE), celebrating five years of support to life-changing projects from the non-profit community. Established in 2018 to enhance the company’s impact on health and well-being, BSFE provides a valuable contribution to the company’s Environmental, Social and Governance commitment.— Read more
Our commitment to quality
Our Best4 quality strategy yields 97% effectiveness in corrective and preventative actions (CAPA) metrics and 99% on-time CAPA approvals.